Evidence map›Paper›PMID 40126084›Full record

ArticleChembiochem : a European journal of chemical biology2025

Target-Guided Design and Synthesis of Aryl-Functionalized Promysalin Analogs.

Martina M Golden, Carter U Brzezinski, William M Wuest

Abstract read
In one paragraph

Article in Chembiochem : a European journal of chemical biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Martina M GoldenDepartment of Chemistry, Emory University, Atlanta, GA, 30322, USA.
Carter U BrzezinskiDepartment of Chemistry, Emory University, Atlanta, GA, 30322, USA.
William M WuestDepartment of Chemistry, Emory University, Atlanta, GA, 30322, USA.ORCID https://orcid.org/0000-0002-5198-7744

Funding

Natural Product-Inspired Approaches Toward The Development Of Antivirulence And Species-Specific InhibitorsR35GM119426 · NIGMS · TEMPLE UNIV OF THE COMMONWEALTH · PI William M Wuest · 2016 to 2026
$4.8M
Atlanta Network for Training In KUH Scientific Research (ATLANTIS)TL1DK136047 · NIDDK · EMORY UNIVERSITY · PI Vivien Andrea Sheehan · 2022 to 2026
$3.0M
Antimicrobial Resistance and Therapeutic Discovery Training ProgramT32AI106699 · NIAID · EMORY UNIVERSITY · PI Graeme L Conn, Joanna B Goldberg · 2014 to 2026
$2.7M
NIAID NIH HHS T32 AI106699NIDDK NIH HHS T32 TL1DK136047NIDDK NIH HHS TL1 DK136047NIGMS NIH HHS R35 GM119426
6 · The paper itself

Abstract

The development of new narrow-spectrum antibiotics is a promising approach to combat antibiotic resistance. Promysalin, a secondary metabolite isolated from Pseudomonas putida, exhibits potent species-specific inhibition of the pathogen P. aeruginosa (IC

Indexed as

Anti-Bacterial AgentsPseudomonas aeruginosaPyrrolidinesSalicylamidesEnzyme InhibitorsMolecular Docking SimulationSuccinate DehydrogenaseAnti-Bacterial AgentsEnzyme InhibitorspromysalinPyrrolidinesSalicylamidesSuccinate Dehydrogenaseantibacterialsdivergent synthesesmolecular dockingspromysalinsPseudomonas aeruginosa

Identifiers

PMID40126084
PMCPMC12119218

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.